Seeking Alpha

IsoRay seeds implanted into human prostate for first time; shares spike

  • IsoRay (ISR) shares jump 12.9% after the company says that its Cesium-131 seeds have been inserted into a human prostate for the first time.
  • Steven Frank of the Anderson Cancer Center, who performed the implant, said that with its short half-life, Cesium-131 "offers rapid resolution of the acute side effects that can be associated with prostate treatment with brachytherapy".
  • IsoRay's technology enables doctors to directly place radiation in areas where cancer is most likely to remain after a tumor is removed. (PR)
Comments (1)
  • LynNorstad
    , contributor
    Comment (1) | Send Message
    This is incorrect. I had ISR Cesium 131 implants 6 years ago, and I was not the first.


    You left out one very important detail ...


    This was the first human prostate implantation in combination with C4 Imaging's Sirius positive signal MRI markers.
    8 Apr, 12:55 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Tools
Find the right ETFs for your portfolio:
Seeking Alpha's new ETF Hub
ETF Investment Guide:
Table of Contents | One Page Summary
Read about different ETF Asset Classes:
ETF Selector